1. Bu, Liang, Jiang, Guanchao, Yang, Fan, Liu, Jun, Wang, Jun. 2011. Highly expressed SLC35F2 in non-small cell lung cancer is associated with pathological staging. In Molecular medicine reports, 4, 1289-93. doi:10.3892/mmr.2011.572. https://pubmed.ncbi.nlm.nih.gov/21874247/
2. Kotolloshi, Roland, Hölzer, Martin, Gajda, Mieczyslaw, Grimm, Marc-Oliver, Steinbach, Daniel. 2021. SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. In Cells, 10, . doi:10.3390/cells10010080. https://pubmed.ncbi.nlm.nih.gov/33418944/
3. Chen, Mei, Gao, Xin, Huang, Denggao, Cao, Hui, Zhang, Shufang. 2019. Knockdown of SLC35F2 Inhibits the Proliferation and Metastasis of Bladder Cancer Cells. In OncoTargets and therapy, 12, 10771-10786. doi:10.2147/OTT.S229332. https://pubmed.ncbi.nlm.nih.gov/31849485/
4. Chandrasekaran, Arun Pandian, Kaushal, Kamini, Park, Chang-Hwan, Kim, Kye-Seong, Ramakrishna, Suresh. 2021. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. In Theranostics, 11, 9752-9771. doi:10.7150/thno.63806. https://pubmed.ncbi.nlm.nih.gov/34815782/
5. Zheng, Qingzhu, Li, Mingjie, Qiu, Yingkun, Yang, Jiahao, Cao, Yingping. 2023. Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinoma. In Heliyon, 10, e23828. doi:10.1016/j.heliyon.2023.e23828. https://pubmed.ncbi.nlm.nih.gov/38187235/
6. Nyquist, Michael D, Corella, Alexandra, Burns, John, Nelson, Peter S, Mostaghel, Elahe A. . Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. In Molecular cancer research : MCR, 15, 521-531. doi:10.1158/1541-7786.MCR-16-0315-T. https://pubmed.ncbi.nlm.nih.gov/28465296/
7. Chiou, Jing-Ting, Lee, Yuan-Chin, Huang, Chia-Hui, Shi, Yi-Jun, Chang, Long-Sen. 2021. Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells. In Biochemical pharmacology, 188, 114544. doi:10.1016/j.bcp.2021.114544. https://pubmed.ncbi.nlm.nih.gov/33831396/